Proteomics International Laboratories Ltd

ASX:PIQ ISIN:AU000000PIQ0

Proteomics International Laboratories LtdProteomics International Laboratories (ASX:PIQ) is a wholly owned subsidiary and trading name of PILL, a medical technology company at the forefront of predictive diagnostics and bioanalytical services. The Company specialises in the area of proteomics - the industrial scale study of the structure and function of proteins. Proteomics International's mission is to improve the quality of lives by the creation and application of innovative tools that enable the improved treatment of disease.

 
 
  

View in Other Languages

News

Proteomics International Laboratories Ltd (ASX:PIQ) European Patent Granted for OxiDx Technology

🕔2/28/2024 8:07:34 AM 845

Proteomics International Laboratories Ltd (ASX:PIQ), a pioneer in predictive diagnostics, is pleased to announce that its subsidiary OxiDx Pty Ltd, has been granted a patent in 19 major European countries for its platform technology to measure oxidative stress.

Read Full Article

Proteomics International Laboratories Ltd (ASX:PIQ) Investor presentation - Euroz Hartleys Healthcare Forum

🕔2/6/2024 9:21:46 AM 1295

Proteomics International Laboratories Ltd (ASX:PIQ) is pleased to release a copy of the presentation to be provided by Dr Richard Lipscombe to delegates at Euroz Hartleys Healthcare Forum being held on 6 February 2024.

Read Full Article

Proteomics International Laboratories Ltd (ASX:PIQ) Study Validates Biomarkers for Endometriosis Blood Test

🕔2/1/2024 9:41:14 AM 1495

Proteomics International Laboratories Ltd (ASX:PIQ), a pioneer in predictive diagnostics is pleased to announce a milestone for its novel blood test for endometriosis, PromarkerEndo, with the clinical validation of the biomarker panel in an independent patient group.

Read Full Article

Proteomics International Laboratories Ltd (ASX:PIQ) Study Validates Biomarkers for Oesophageal Cancer Blood Test

🕔2/1/2024 9:40:49 AM 1364

Proteomics International Laboratories Ltd (ASX:PIQ), a pioneer in predictive diagnostics is pleased to announce a milestone for its novel blood test for oesophageal adenocarcinoma, PromarkerEso, with the clinical validation of the biomarker panel in a second independent patient group.

Read Full Article

Proteomics International Laboratories Ltd (ASX:PIQ) To Raise $6.5m Through Institutional Placement

🕔1/23/2024 9:15:41 AM 1588

Proteomics International Laboratories Ltd (ASX:PIQ), a pioneer in predictive diagnostics is pleased to announce that it has received firm commitments from new and existing institutional investors for a non-underwritten placement of 8.6 million new fully paid ordinary shares.

Read Full Article

Proteomics International Laboratories Ltd (ASX:PIQ) December 2023 Quarterly Activities Report

🕔1/23/2024 8:57:11 AM 1173

Proteomics International Laboratories Ltd (ASX:PIQ), a medical technology company at the forefront of precision medicine and predictive diagnostics, is pleased to provide the following update on its business activities for the three months to 31 December 2023 and subsequent to the period end.

Read Full Article

Proteomics International Laboratories Ltd (ASX:PIQ) PromarkerD Licence with Omics Global Extended to Chile

🕔12/20/2023 9:12:03 AM 2474

Proteomics International Laboratories Ltd (ASX:PIQ) is pleased to announce the signing of a licence agreement to expand PromarkerD's reach in Central and South America.

Read Full Article

Proteomics International Laboratories Ltd (ASX:PIQ) AGM Chairman's Address and Investor Presentation

🕔11/23/2023 12:22:57 PM 1604

Proteomics International Laboratories Ltd (ASX:PIQ) is pleased to release a copy of the Chairman's Address provided by Mr Neville Gardiner and the Investor Presentation provided by Dr Richard Lipscombe to shareholders.

Read Full Article

Proteomics International Laboratories Ltd (ASX:PIQ) US Medicare Confirms Reimbursement Price for PromarkerD

🕔11/22/2023 9:13:14 AM 1568

Proteomics International Laboratories Ltd (ASX:PIQ) is pleased to announce that the US Centers for Medicare & Medicaid Services has published its final determination of the national reimbursement price in the United States for the PromarkerD predictive test for diabetic kidney disease.

Read Full Article

Proteomics International Laboratories Ltd (ASX:PIQ) Presents at Bell Potter Healthcare Conference

🕔11/13/2023 9:13:49 AM 1693

Proteomics International Laboratories Ltd (ASX:PIQ) is pleased to provide an opportunity for shareholders and investors to view a virtual presentation by Managing Director Dr Richard Lipscombe.

Read Full Article
###

9,225 COMPANY PROFILE VIEWS

  • This Page Viewed: (Last 7 Days: 257) (Last 30 Days: 645) (Since Published: 7992) 

Company Data

    Headquarters
  • QEII Medical Centre
    6 Verdun Street
    Nedlands WA 6009
    Australia
  • Telephone
  • +61-8-9389-1992 
  • Principal Sector
  • Biotech 
  • Principal Industry
  • Biotechnology 
  • Homepage
  • www.proteomics.com.au

Company Reports